HBIO vs LMAT vs ITRN vs ATRC

For growth investors, AtriCure, Inc.

(ATRC) is the stronger pick with 14. 9% revenue growth year-over-year, versus -8. 1% for Harvard Bioscience, Inc. (HBIO). Ituran Location and Control Ltd. (ITRN) offers the better valuation at 20. 9x trailing P/E (18. 4x forward), making it the more compelling value choice. Analysts rate Harvard Bioscience, Inc. (HBIO) a "Buy" — based on 5 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Ituran Location and Control Ltd.

(ITRN) is the cheapest at 20. 9x versus LeMaitre Vascular, Inc. at 42. 8x. On forward P/E, Ituran Location and Control Ltd. is actually cheaper at 18. 4x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Ituran Location and Control Ltd. wins at 0. 60x versus LeMaitre Vascular, Inc. 's 1. 87x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.

Over the past 5 years, Ituran Location and Control Ltd.

(ITRN) delivered a total return of +193. 1%, compared to -90. 1% for Harvard Bioscience, Inc. (HBIO). Over 10 years, the gap is even starker: LMAT returned +608. 8% versus HBIO's -75. 8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), LeMaitre Vascular, Inc.

(LMAT) is the lower-risk stock at 0. 71β versus Harvard Bioscience, Inc. 's 2. 05β — meaning HBIO is approximately 190% more volatile than LMAT relative to the S&P 500. On balance sheet safety, Ituran Location and Control Ltd. (ITRN) carries a lower debt/equity ratio of 2% versus 3% for Harvard Bioscience, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), AtriCure, Inc.

(ATRC) is pulling ahead at 14. 9% versus -8. 1% for Harvard Bioscience, Inc. (HBIO). On earnings-per-share growth, the picture is similar: AtriCure, Inc. grew EPS 74. 7% year-over-year, compared to -357. 1% for Harvard Bioscience, Inc.. Over a 3-year CAGR, ATRC leads at 17. 4% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

LeMaitre Vascular, Inc.

(LMAT) is the more profitable company, earning 23. 1% net margin versus -65. 5% for Harvard Bioscience, Inc. — meaning it keeps 23. 1% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: LMAT leads at 27. 2% versus -0. 7% for HBIO. At the gross margin level — before operating expenses — ATRC leads at 74. 4%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, Ituran Location and Control Ltd. (ITRN) is the more undervalued stock at a PEG of 0. 60x versus LeMaitre Vascular, Inc. 's 1. 87x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, Ituran Location and Control Ltd. (ITRN) trades at 18. 4x forward P/E versus 428. 7x for AtriCure, Inc. — 410. 3x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for ATRC: 95. 3% to $51. 33.

In this comparison, ITRN (3.

1% yield), LMAT (0. 7% yield) pay a dividend. HBIO, ATRC do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, LeMaitre Vascular, Inc.

(LMAT) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 71), 0. 7% yield, +608. 8% 10Y return). Harvard Bioscience, Inc. (HBIO) carries a higher beta of 2. 05 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (LMAT: +608. 8%, HBIO: -75. 8%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (HBIO (Healthcare) and LMAT (Healthcare) and ITRN (Technology) and ATRC (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: HBIO is a small-cap quality compounder stock; LMAT is a small-cap quality compounder stock; ITRN is a small-cap income-oriented stock; ATRC is a small-cap quality compounder stock. LMAT, ITRN pay a dividend while HBIO, ATRC do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.